AKAGI, ERICA M.SA JUNIOR, PAULO L. deSIMONS, SIMONE M.BELLINI, MARIA H.BARRETO, SANDRA A.CHUDZINSKI-TAVASSI, ANA M.2014-07-152014-07-302014-07-152014-07-302012AKAGI, ERICA M.; SA JUNIOR, PAULO L. de; SIMONS, SIMONE M.; BELLINI, MARIA H.; BARRETO, SANDRA A.; CHUDZINSKI-TAVASSI, ANA M. Pro-apoptotic effects of amblyomin-X in murine renal cell carcinoma 'in-vitro'. <b>Biomedicine and Pharmacotherapy</b>, v. 66, n. 1, p. 64-69, 2012. DOI: <a href="https://dx.doi.org/10.1016/j.biopha.2011.11.015">10.1016/j.biopha.2011.11.015</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/4296.0753-3322http://repositorio.ipen.br/handle/123456789/4296Renal cell carcinoma (RCC) is one of the most lethal urologic cancers and is highly resistant to both radiotherapy and chemotherapy. The recombinant protein Amblyomin-X, characterized as a Kunitz-type protease inhibitor, was obtained from a cDNA library from the salivary glands of the Amblyomma cajennense tick. This paper reports the biological effect of Amblyomin-X on inducing cell death by apoptotic process in vitro. For this purpose, the changes in morphological aspects of cells, the phosphatidylserine exposition and DNA degradation were evaluated after treatment with Amblyomin- X. We found that Amblyomin-X was able to induce apoptosis in Renca cells in a dose-dependent manner. So, the results presented here open perspectives for new researches and developing for Amblyomin-X in the treatment of RCC.64-69openAccesscarcinomasrenal clearancetumor cellsbiological materialssalivary glandsparasitesapoptosisArtigo de periódico16610.1016/j.biopha.2011.11.015https://orcid.org/0000-0003-2852-618944.01